Literature DB >> 33992030

The Inside-Out of End-Stage Liver Disease: Hepatocytes are the Keystone.

Nils Haep1, Rodrigo M Florentino1, James E Squires2,3, Aaron Bell1,3, Alejandro Soto-Gutierrez1,3.   

Abstract

Chronic liver injury results in cirrhosis and end-stage liver disease (ESLD) which represents a leading cause of death worldwide, affecting people in their most productive years of life. Medical therapy can extend life, but the only definitive treatment is liver transplantation (LT). However, LT remains limited by access to quality donor organs and suboptimal long-term outcomes. The degeneration from healthy-functioning livers to cirrhosis and ESLD involves a dynamic process of hepatocyte damage, diminished hepatic function, and adaptation. However, the mechanisms responsible for deterioration of hepatocyte function and ultimately hepatic failure in man are poorly understood. We review the current understanding of cirrhosis and ESLD as a dynamic process and outline the current mechanisms associated with the development of hepatic failure from the clinical manifestations to energy adaptations, regeneration, and regulation of nuclear transcription factors. A new generation of therapeutics could target stabilization of hepatocyte differentiation and function to avoid the need for transplantation in patients with cirrhosis and ESLD. Thieme. All rights reserved.

Entities:  

Mesh:

Year:  2021        PMID: 33992030      PMCID: PMC8996333          DOI: 10.1055/s-0041-1725023

Source DB:  PubMed          Journal:  Semin Liver Dis        ISSN: 0272-8087            Impact factor:   6.115


  114 in total

Review 1.  Functional aspects on the pathophysiology of portal hypertension in cirrhosis.

Authors:  Juan-Carlos García-Pagán; Jorge Gracia-Sancho; Jaume Bosch
Journal:  J Hepatol       Date:  2012-04-12       Impact factor: 25.083

2.  Hepatic venous pressure gradient in 2010: optimal measurement is key.

Authors:  Andrew K Burroughs; Ulrich Thalheimer
Journal:  Hepatology       Date:  2010-06       Impact factor: 17.425

Review 3.  Cirrhosis of the liver: a reversible disease?

Authors:  R Pérez-Tamayo
Journal:  Pathol Annu       Date:  1979

Review 4.  Renal failure and cirrhosis: a systematic review of mortality and prognosis.

Authors:  Giuseppe Fede; Gennaro D'Amico; Vasiliki Arvaniti; Emmanuel Tsochatzis; Giacomo Germani; Dimosthenis Georgiadis; Alberto Morabito; Andrew Kenneth Burroughs
Journal:  J Hepatol       Date:  2011-12-13       Impact factor: 25.083

5.  Loss of Gsα impairs liver regeneration through a defect in the crosstalk between cAMP and growth factor signaling.

Authors:  Changli Lu; Jie Xia; Yongjie Zhou; Xufeng Lu; Lei Zhang; Maling Gou; Lei Li; Xiaoyun Zhang; Hongjie Ji; Keting Zhu; Li Li; Jie Zhang; Ping Yu; Jiayin Yang; Hong Bu; Yujun Shi
Journal:  J Hepatol       Date:  2015-09-18       Impact factor: 25.083

Review 6.  Angiogenesis in liver disease.

Authors:  Mercedes Fernández; David Semela; Jordi Bruix; Isabelle Colle; Massimo Pinzani; Jaume Bosch
Journal:  J Hepatol       Date:  2008-12-31       Impact factor: 25.083

7.  Structural and functional impairment of mitochondria from rat livers chronically injured by thioacetamide.

Authors:  B Möller; R Dargel
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1984-08

8.  Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017.

Authors: 
Journal:  Lancet       Date:  2018-11-08       Impact factor: 79.321

9.  In vivo reprogramming of adult pancreatic exocrine cells to beta-cells.

Authors:  Qiao Zhou; Juliana Brown; Andrew Kanarek; Jayaraj Rajagopal; Douglas A Melton
Journal:  Nature       Date:  2008-08-27       Impact factor: 49.962

10.  Liver-enriched transcription factor expression relates to chronic hepatic failure in humans.

Authors:  Jorge Guzman-Lepe; Eduardo Cervantes-Alvarez; Alexandra Collin de l'Hortet; Yang Wang; Wendy M Mars; Yoshinao Oda; Yuki Bekki; Masahiro Shimokawa; Huanlin Wang; Tomoharu Yoshizumi; Yoshihiko Maehara; Aaron Bell; Ira J Fox; Kazuki Takeishi; Alejandro Soto-Gutierrez
Journal:  Hepatol Commun       Date:  2018-03-23
View more
  1 in total

Review 1.  Therapeutic Potential of HNF4α in End-stage Liver Disease.

Authors:  Ricardo Diaz-Aragon; Michael C Coard; Sriram Amirneni; Lanuza Faccioli; Nils Haep; Michelle R Malizio; Takashi Motomura; Zehra N Kocas-Kilicarslan; Alina Ostrowska; Rodrigo M Florentino; Carla Frau
Journal:  Organogenesis       Date:  2021-10-02       Impact factor: 2.316

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.